Introgen Therapeutics, Inc.

(NASDAQ:INGN)

Key Stats & Ratios

Valuation
Market Cap 2.65M
P/E
P/E (Trailing) -0.10
P/E (Forward)
Price/Sales 2.00
Price/Book 5.80
EPS -0.55
EPS Growth (ttm)
Fiscal Year
Fiscal Year Ends Dec 31
Last Quarter Jun 2008
Profitability
Operating Income -29499000.00
Net Income -24265000.00
Profit Margin (ttm)
Operating Margin (ttm) -26.67%
Management Effectiveness
Return on Assets (ttm) -225.00%
Return on Equity (ttm)
EBIT Margin (ttm)
SEC Filings
Latest Form 10-Q (Quartely)
Latest Form 10-K (Annual)

Financials

Income Statement
Total Enterprise Value 3.25M
Revenue 1.11M
Revenue/Share 0.03
Revenue Growth (ytd) 17.50%
Annual Revenue Growth Rate (3Y) -18.57%
Annual Income Growth Rate (3Y)
Earnings Growth (ytd)
Gross Operating Profit (ttm) 2.08M
EBITDA -28523000.00
Diluted EPS (ttm) -0.55
Balance Sheet
Total Cash 6.18M
Total Cash/Share 0.14
Total Assets 10.78M
Total Liabilities 13.29M
Total Debt/Equity 3.00
Long Term Debt Common Equity Ratio 2.96
Current Ratio 1.00
Leverage Ratio 6.00
Book Value/Share 0.05
Cash Flow
Cash Flow -23289000.00
Free Cash Flow -15549000.00
Cash Flow/Share -0.53
Free Cash Flow/Share -0.35

Trading Information

Stock Price History
Beta
52Wk Change -98.50%
52Wk Change Vs. Mkt -98.00%
52Wk High 4.62
52Wk Low 0.05
10 Day Moving Average 0.21
200 Day Moving Average 1.54
Share Statistics
Average Volume 459.70K
Shares Outstanding 44.14M
Shares Float 38.02M
% Held by Insiders 13.90%
% Held by Institutions 24.80%
Shares Short (As of Nov 11, 2008) 2.81M
Short Ratio 28.00
Short % of Float 7.40%
Dividends & Splits
Dividend Date
Dividend Yield
Dividend Amount